# Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)

> **NCT04046224** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sangamo Therapeutics** · enrollment: 36 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **BIOLOGICAL:** ST-920

## Key facts

- **NCT ID:** NCT04046224
- **Lead sponsor:** Sangamo Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-23
- **Primary completion:** 2025-04-10
- **Final completion:** 2025-04-10
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04046224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04046224, "Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04046224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*